Every material Form 8-K ScanSource filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ScanSource entered a new credit agreement with PNC Bank on December 18, 2025, providing a $400 million revolving credit facility and a $100 million term loan, and borrowed the full $100 million term loan that day. The company used the proceeds to repay and terminate its prior $500 million JPMorgan Chase credit agreement, which had been scheduled to expire or mature on September 28, 2027. The new facilities are secured by substantially all company and domestic subsidiary assets and carry leverage and interest coverage covenants.
New credit agreement with PNC Bank: $400 million five-year revolver plus $100 million five-year term loan, dated December 18, 2025
$100 million term loan drawn on December 18, 2025
Prior $500 million JPMorgan Chase credit agreement terminated and repaid on December 18, 2025
Covenants require leverage ratio of 3.50 to 1.00 or less and interest coverage of at least 3.00 to 1.00
ScanSource reported first-quarter fiscal 2026 results for the quarter ended September 30, 2025, with net sales down 4.6% year over year to $739.7 million while GAAP diluted EPS rose 29% to $0.89. The company reaffirmed its full-year fiscal 2026 outlook of $3.1 billion to $3.3 billion in net sales and $150 million to $160 million in adjusted EBITDA. Shareholders see lower sales offset by higher per-share profit, and the reaffirmed outlook means no change to guidance.
Net sales were $739.7 million, down 4.6% from $775.6 million a year earlier; gross profit rose 5.8% to $107.5 million.
GAAP net income was $19.9 million, or $0.89 per diluted share, versus $0.69 a year earlier; non-GAAP diluted EPS was $1.06, up 26.2%.
Share repurchases totaled $21.3 million in the quarter, and cash and cash equivalents were $124.9 million as of September 30, 2025.
FY26 outlook was reaffirmed: net sales of $3.1 billion to $3.3 billion, adjusted EBITDA of $150 million to $160 million, and free cash flow of at least $80 million.
ScanSource reported fourth-quarter and fiscal 2025 results for the year ended June 30, 2025. Q4 net sales rose 8.9% and GAAP diluted EPS rose to $0.88 from $0.64, while full-year net sales fell 6.7% and GAAP diluted EPS slipped to $3.00 from $3.06. The company also issued fiscal 2026 guidance calling for net sales of $3.1 billion to $3.3 billion and adjusted EBITDA of $150 million to $160 million.
Q4 FY25 net sales were $812.9 million, up 8.9% year over year, and GAAP diluted EPS was $0.88 versus $0.64.
FY25 net sales were $3.04 billion, down 6.7%, and GAAP diluted EPS was $3.00 versus $3.06; non-GAAP diluted EPS was $3.57 versus $3.08.
FY26 outlook: net sales of $3.1 billion to $3.3 billion, adjusted EBITDA of $150 million to $160 million, and free cash flow of at least $80 million.
At June 30, 2025, cash was $126.2 million and total debt was $136.1 million; FY25 share repurchases totaled $106.5 million.
ScanSource reported fiscal third-quarter 2025 net sales of $704.8 million, down 6.3% year over year, while GAAP diluted EPS rose to $0.74 from $0.50. The company replaced its fiscal 2025 outlook, now expecting net sales of approximately $3 billion and adjusted EBITDA of $140 million to $145 million, and announced a new $200 million share repurchase authorization.
Q3 net sales were $704.8 million, down 6.3%; GAAP net income was $17.4 million, or $0.74 per diluted share, versus $0.50 a year earlier
Non-GAAP diluted EPS was $0.86, up 24.6%; adjusted EBITDA rose 5.9% to $35.1 million
FY25 outlook: net sales of approximately $3 billion (prior $3.1 billion to $3.5 billion); adjusted EBITDA of $140 million to $145 million (prior $140 million to $160 million); free cash flow at least $70 million, unchanged
Board approved a new $200 million buyback; about $42 million remained under the existing authorization as of March 31, 2025
ScanSource reported fiscal second-quarter 2025 results for the quarter ended December 31, 2024, with net sales down 15.5% year over year and GAAP net income down 47.9%. The company reaffirmed its fiscal 2025 outlook and said its CEO, Mike Baur, was also appointed President effective January 27, 2025, with no change to his compensation.
Net sales were $747.5 million versus $884.8 million a year earlier; gross profit rose 1.0% to $101.7 million.
GAAP diluted EPS was $0.70 versus $1.29; non-GAAP diluted EPS was $0.85, unchanged year over year.
Fiscal 2025 outlook reaffirmed: net sales $3.1 billion to $3.5 billion and adjusted EBITDA $140 million to $160 million.
Mike Baur, Chair and CEO, was appointed President effective January 27, 2025, and his compensation will not change.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ScanSource filing is on SEC EDGAR ↗. 8-K briefs of other companies →